Ewing sarcoma

What is Ewing sarcoma?

Ewing sarcoma is a rare and aggressive bone and soft tissue cancer that primarily affects children, adolescents, and young adults. This malignant tumor most commonly develops in the bones of the pelvis, chest wall, and long bones of the arms and legs, though it can also arise in soft tissues. With a prevalence of approximately 1 in 1,000,000 people, Ewing sarcoma represents the second most common primary bone cancer in pediatric patients. The condition is characterized by a specific genetic alteration involving the EWSR1 gene fusion, which drives the abnormal cell growth and tumor formation.

Key statistics

Symptoms

Common symptoms: Persistent bone pain, swelling at tumor site, pathologic fractures, fever, fatigue, weight loss, limited range of motion.

The hallmark symptom of Ewing sarcoma is persistent, deep bone pain that typically worsens at night and may not respond to over-the-counter pain medications. Unlike growing pains, this discomfort is localized to a specific area and progressively intensifies over weeks or months. Swelling often accompanies the pain, creating a noticeable mass that may feel warm to the touch.

Pathologic fractures can occur when the tumor weakens the bone structure, causing breaks during normal activities or minor trauma. Constitutional symptoms frequently develop as the disease progresses, including unexplained fever, fatigue, and unintentional weight loss. Patients may also experience limited mobility in the affected limb or joint, particularly when tumors involve the pelvis or spine.

Submit Your Paper

When Ewing sarcoma affects the chest wall or ribs, patients might develop breathing difficulties, chest pain, or a persistent cough. Spinal involvement can lead to back pain, neurological symptoms, or in severe cases, paralysis if the tumor compresses the spinal cord.

Causes and risk factors

Ewing sarcoma is caused by somatic genetic mutations, specifically chromosomal translocations involving the EWSR1 gene. The most common alteration is a fusion between EWSR1 and FLI1 genes, found in approximately 85% of cases. These genetic changes occur randomly during a person’s lifetime and are not inherited from parents, meaning the condition is not passed down through families.

The exact trigger for these genetic alterations remains unknown. Unlike many other cancers, Ewing sarcoma has few identified environmental risk factors. Age represents the primary risk factor, with 90% of cases occurring before age 30. The condition shows a striking demographic pattern, affecting Caucasian populations significantly more frequently than other ethnic groups.

Previous radiation exposure has been associated with a slightly increased risk, though this accounts for only a small percentage of cases. Some research suggests potential links to bone injuries or rapid bone growth during adolescence, but these connections remain unproven.

Prevention

Currently, no evidence-based prevention strategies exist for Ewing sarcoma due to its sporadic nature and unknown environmental triggers. Since the genetic mutations occur randomly and are not inherited, genetic counseling or carrier testing is not applicable for family members.

However, early detection through awareness of symptoms can significantly impact outcomes. Parents and healthcare providers should maintain vigilance for persistent bone pain in children and adolescents, particularly pain that worsens at night or doesn’t resolve with rest. Regular pediatric checkups provide opportunities to identify concerning symptoms early in the disease course.

Complications

Without treatment, Ewing sarcoma is uniformly fatal, typically within 6-12 months of diagnosis. The tumor’s aggressive nature leads to rapid local growth and early metastatic spread, most commonly to the lungs, other bones, and bone marrow.

Local complications include severe bone destruction, pathologic fractures, and compression of surrounding structures. When tumors affect the spine, untreated disease can cause permanent neurological damage or paralysis. Chest wall involvement may lead to respiratory compromise.

Metastatic disease significantly worsens the prognosis, with lung metastases being particularly concerning. The systemic nature of advanced disease can cause bone marrow suppression, leading to anemia, increased infection risk, and bleeding complications.

Even with treatment, survivors may face long-term complications including growth abnormalities, secondary cancers from chemotherapy or radiation, fertility issues, cardiac problems, and chronic pain or disability related to surgical interventions.

Diagnosis

Diagnosing Ewing sarcoma requires a multidisciplinary approach combining clinical evaluation, imaging studies, and tissue analysis. Initial imaging typically includes plain radiographs of the affected area, which may show characteristic findings such as bone destruction with an “onion skin” periosteal reaction.

Advanced imaging studies are essential for proper staging and treatment planning. Magnetic resonance imaging (MRI) provides detailed visualization of soft tissue extension and helps define surgical margins. Computed tomography (CT) scans of the chest are performed to detect pulmonary metastases.

Tissue biopsy remains the definitive diagnostic method, requiring careful planning to avoid compromising future surgical options. Pathological examination reveals small, round, blue cells that are characteristic but not specific to Ewing sarcoma. Immunohistochemistry testing shows positive staining for CD99 in most cases.

Molecular genetic testing is crucial for confirmation, identifying the pathognomonic EWSR1 gene rearrangements through fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR). Additional staging studies include bone marrow biopsy, bone scan, and positron emission tomography (PET) scan to detect distant disease.

Treatment

Treatment of Ewing sarcoma requires intensive multimodal therapy combining chemotherapy, surgery, and often radiation therapy. The standard approach begins with neoadjuvant chemotherapy to shrink the tumor and treat potential microscopic metastases.

First-line chemotherapy regimens typically include vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide. Treatment duration extends 6-9 months with intensive cycles requiring hospitalization and supportive care.

Local control is achieved through surgical resection when feasible, aiming for complete tumor removal with clear margins. Limb-salvage procedures are preferred when possible to preserve function, though amputation may be necessary in some cases. Reconstruction techniques using prostheses or bone grafts help restore limb function.

Radiation therapy serves as an alternative or adjunct to surgery, particularly for tumors in locations where complete surgical resection is not possible. Modern techniques like intensity-modulated radiation therapy (IMRT) help minimize damage to surrounding healthy tissues.

For relapsed or refractory disease, investigational agents include temozolomide, irinotecan, and targeted therapies. Clinical trials may offer access to novel treatments including immunotherapy approaches and precision medicine strategies.

Prognosis

The prognosis for Ewing sarcoma depends heavily on disease extent at diagnosis and response to treatment. Patients with localized disease have 5-year survival rates of 70-80% with current multimodal therapy. However, outcomes remain significantly worse for patients presenting with metastatic disease, where 5-year survival drops to 30-40%.

Factors associated with better prognosis include younger age at diagnosis, smaller tumor size, favorable anatomic location, and good response to initial chemotherapy. Tumors arising in the extremities generally have better outcomes compared to axial locations like the pelvis or spine.

The response to neoadjuvant chemotherapy, measured by the degree of tumor necrosis in surgical specimens, strongly correlates with long-term survival. Patients achieving greater than 90% necrosis have significantly improved outcomes compared to poor responders.

Long-term survival is possible with aggressive treatment, though survivors require lifelong monitoring for treatment-related complications and secondary malignancies. Quality of life can be good for survivors, particularly when limb-salvage procedures successfully preserve function.

Quality of life

Living with Ewing sarcoma presents significant challenges during treatment and recovery. The intensive chemotherapy regimens require frequent hospitalizations and can cause substantial side effects including nausea, fatigue, hair loss, and increased infection risk. Nutritional support becomes crucial as appetite decreases and energy needs increase.

During treatment, maintaining some level of physical activity as tolerated helps preserve muscle strength and bone density. Physical therapy plays a vital role in rehabilitation, particularly after limb-salvage surgery or amputation. Occupational therapy helps patients adapt to functional limitations and return to daily activities.

Educational accommodations may be necessary during treatment, with many patients benefiting from home tutoring or modified school schedules. Emotional support through counseling, support groups, or peer connections helps patients and families cope with the psychological impact of cancer diagnosis and treatment.

Pain management strategies combine medications with complementary approaches like relaxation techniques, distraction therapy, and when appropriate, physical modalities. Sleep quality often improves as treatment progresses and pain decreases.

Career and educational planning may require modifications based on functional limitations, but many survivors achieve their academic and professional goals with appropriate accommodations and support.

Pregnancy and fertility

Ewing sarcoma treatment can significantly impact fertility in both male and female patients. Chemotherapy agents, particularly cyclophosphamide and ifosfamide, carry substantial risks for gonadal dysfunction and infertility.

Fertility preservation options should be discussed before treatment initiation. For post-pubertal males, sperm banking offers the most established preservation method. Females may benefit from oocyte or embryo cryopreservation, though the time-sensitive nature of cancer treatment may limit options.

For patients who become pregnant after treatment, close monitoring is essential due to potential cardiac effects from doxorubicin and other treatment-related complications. Most chemotherapy agents used for Ewing sarcoma are contraindicated during pregnancy, making treatment timing crucial for females of reproductive age.

Genetic counseling can provide reassurance that Ewing sarcoma is not inherited, meaning survivors do not have an increased risk of passing the condition to their children.

Children

Ewing sarcoma predominantly affects the pediatric population, requiring specialized care within pediatric oncology centers. Children face unique challenges including growth and development concerns during treatment, educational disruption, and long-term effects on physical and cognitive development.

Growth monitoring is essential as chemotherapy and radiation can affect normal development. Nutritional support becomes even more critical in growing children, often requiring aggressive interventions to maintain adequate caloric intake during treatment.

Psychosocial support must address age-appropriate concerns, from separation anxiety in younger children to body image and peer relationships in adolescents. Child life specialists play crucial roles in helping patients cope with hospitalization and medical procedures.

Late effects monitoring in pediatric survivors includes assessment for secondary cancers, cardiac function, fertility, and psychosocial development. Transition to adult care requires careful planning and coordination to ensure continuity of surveillance and support services.

When to see a doctor

Immediate medical evaluation is warranted for persistent bone pain lasting more than a few days, particularly pain that worsens at night or doesn’t improve with rest and over-the-counter medications. Any unexplained swelling, especially when accompanied by pain, requires prompt assessment.

Emergency care should be sought for signs of pathologic fracture, severe pain, neurological symptoms like weakness or numbness, or constitutional symptoms including unexplained fever, significant weight loss, or extreme fatigue.

Parents and patients should not dismiss persistent bone pain as growing pains or sports injuries, particularly in adolescents. Any pain that interferes with sleep or daily activities deserves medical attention.

Follow-up care for diagnosed patients requires strict adherence to scheduled appointments and immediate reporting of new symptoms, signs of infection during treatment, or concerns about treatment side effects.

Regional context

Specific prevalence data for Ewing sarcoma in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited due to the rarity of the condition and varying cancer registry capabilities. The Global Medical Journal welcomes contributions from regional oncologists and researchers who can provide insights into local prevalence patterns, treatment accessibility, and outcomes data for Ewing sarcoma in these populations.

Regional factors that may influence care include access to specialized pediatric oncology centers, availability of advanced imaging and molecular diagnostic capabilities, and coordination with international treatment protocols. Telemedicine consultations may help bridge gaps in specialized expertise for patients in remote areas.

Research and clinical trials

Current research in Ewing sarcoma focuses on improving outcomes through novel therapeutic approaches and better understanding of tumor biology. Immunotherapy strategies, including checkpoint inhibitors and adoptive cell therapy, show promise in early-phase trials.

Targeted therapy development aims to exploit the unique molecular characteristics of Ewing sarcoma, particularly therapies directed against the EWSR1-FLI1 fusion protein and its downstream effects. Precision medicine approaches seek to identify biomarkers predictive of treatment response.

Recent breakthroughs include improved understanding of tumor microenvironment interactions and identification of potential therapeutic vulnerabilities. Combination strategies incorporating novel agents with standard chemotherapy are being evaluated in clinical trials.

Patients and families can search for relevant clinical trials through ClinicalTrials.gov, and should discuss trial participation with their oncology team. Enrollment in clinical trials may provide access to promising new treatments while contributing to advancement of care for future patients.

Frequently asked questions

Is Ewing sarcoma hereditary?

No, Ewing sarcoma is not inherited from parents. The genetic changes that cause this cancer occur randomly during a person’s lifetime and are not passed down through families.

Can Ewing sarcoma be cured?

Yes, Ewing sarcoma can be cured, particularly when caught early and confined to the primary site. With intensive treatment, 70-80% of patients with localized disease achieve long-term survival.

Why is Ewing sarcoma more common in Caucasians?

The reason for this demographic pattern is not fully understood. Genetic factors likely contribute to the racial disparity, but specific mechanisms remain under investigation.

How long does treatment take?

Treatment typically lasts 6-9 months and includes intensive chemotherapy cycles, surgery or radiation for local control, and additional chemotherapy. The exact duration depends on individual response and treatment protocol.

What are the chances of Ewing sarcoma coming back?

Recurrence risk depends on initial disease stage and treatment response. Most relapses occur within the first 2-3 years after treatment completion, emphasizing the importance of close follow-up care.

Support and resources

International Organizations:
– Orphanet: www.orpha.net
– National Organization for Rare Disorders (NORD): rarediseases.org
– EURORDIS: www.eurordis.org
– Sarcoma Alliance: sarcomaalliance.org
– Liddy Shriver Sarcoma Initiative: sarcomahelp.org
– Children’s Oncology Group: childrensoncologygroup.org

Related conditions

Osteosarcoma
Rhabdomyosarcoma
Synovial sarcoma
Primitive neuroectodermal

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.